← Leaderboards
Howard L Weiner
Brigham And Women'S Hospital
$38,267,107
Attributed
$41,598,202
Total exposure
29
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$60,001,434 · 31
By mechanism
R01$26,788,444 · 10
P01$22,655,044 · 7
RF1$3,179,376 · 1
R42$2,550,000 · 1
R21$2,208,819 · 5
UH3$1,061,833 · 1
Top collaborators
- Roopali Gandhi8 shared
- Oleg Butovsky4 shared
- Neena B Haider4 shared
- Ilya Ilin3 shared
- Francisco J. Quintana2 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Roopali Gandhi$924,516
- Samia J. Khoury$10,360,565
- Vijay K Kuchroo$71,617,613
- Jean-Pierre M Kinet$18,735,968
- Eugene D. Ponomarev$637,634
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposImmuneInvestigationAnimal ModelCellsT-LymphocytePlayMultiple SclerosisAffectImmune SystemBaseResponseInflammatoryImmunotherapyMacrophagePathway InteractionsExperimental Autoimmune EncephalomyelitisInterestAnimalsDisease ProgressionMicrogliaBrainMediatingImmune Response
Grant awards (116)
Mechanisms underlying the neuroprotective effect of nasal administration of anti-CD3 in AD mouse models$789,540
R01 · FY2025 · AG · contact PI
Role of the Intestinal Microbiota in ALS$690,184
R01 · FY2025 · NS · contact PI
Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in HealthyHuman Subjects$50,000
R42 · FY2025 · AG
Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects$1,181,555
R42 · FY2024 · AG
Mechanisms underlying the neuroprotective effect of nasal administration of anti-CD3 in AD mouse models$805,654
R01 · FY2024 · AG · contact PI
The role of microbiota in aging and Alzheimer's disease$794,844
R01 · FY2024 · AG · contact PI
Role of the Intestinal Microbiota in ALS$669,479
R01 · FY2024 · NS · contact PI
Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects$1,318,445
R42 · FY2023 · AG
Role of the Intestinal Microbiota in ALS$690,184
R01 · FY2023 · NS · contact PI
Role of the Intestinal Microbiota in ALS$107,658
R01 · FY2023 · NS · contact PI
Role of the Intestinal Microbiota in ALS$690,184
R01 · FY2022 · NS · contact PI
Functional and Transcriptional Profiling of Monocytes in Alzheimer's Disease$492,250
R21 · FY2022 · AG · contact PI
Role of the Intestinal Microbiota in ALS$106,970
R01 · FY2022 · NS · contact PI
Role of the Intestinal Microbiota in ALS$709,934
R01 · FY2021 · NS · contact PI
The role of microbiota in aging and Alzheimer's disease$3,179,376
RF1 · FY2020 · AG · contact PI
Targeting CNS neuroinflammation in animal models of Alzheimer's disease$479,610
R21 · FY2020 · AG · contact PI
Role of Microglia in Retinitis Pigementosa$454,680
R01 · FY2019 · EY · contact PI
Role of Microglia in Retinitis Pigementosa$122,264
R01 · FY2019 · EY · contact PI
Role of Microglia in Retinitis Pigementosa$454,680
R01 · FY2018 · EY · contact PI
Gut Microbiota in Patients with Multiple Sclerosis$388,281
R01 · FY2018 · NS · contact PI
Transcriptional Control of Autoimmunity in the Central Nervous System$1,113,572
P01 · FY2017 · NS · contact PI
Role of Microglia in Retinitis Pigementosa$471,550
R01 · FY2017 · EY · contact PI
Gut Microbiota in Patients with Multiple Sclerosis$388,281
R01 · FY2017 · NS · contact PI
Circulating MicroRNAs as Disease Biomarkers in Multiple Sclerosis$325,769
UH3 · FY2017 · TR · contact PI
Molecular Analysis of Effector and Regulatory T cell Responses in MS$252,095
P01 · FY2017 · NS · contact PI
Administrative Core$81,472
P01 · FY2017 · NS · contact PI
Role of the Innate Immune System in Aging and Development of Alzheimer's Disease$1,695,875
R01 · FY2016 · AG · contact PI
Transcriptional Control of Autoimmunity in the Central Nervous System$1,113,572
P01 · FY2016 · NS · contact PI
Gut Microbiota in Patients with Multiple Sclerosis$388,281
R01 · FY2016 · NS · contact PI
Circulating MicroRNAs as Disease Biomarkers in Multiple Sclerosis$325,769
UH3 · FY2016 · TR · contact PI
Molecular Analysis of Effector and Regulatory T cell Responses in MS$252,095
P01 · FY2016 · NS · contact PI
Administrative Core$81,471
P01 · FY2016 · NS · contact PI
Circulating MicroRNAs as Disease Biomarkers in Multiple Sclerosis$44,375
UH3 · FY2016 · TR · contact PI
Evaluation of biofluid exRNA isolation by small RNAseq$44,375
UH3 · FY2016 · TR
Role of the Innate Immune System in Aging and Development of Alzheimer's Disease$1,680,024
R01 · FY2015 · AG · contact PI
Transcriptional Control of Autoimmunity in the Central Nervous System$1,113,572
P01 · FY2015 · NS · contact PI
Mechanisms of the Induction of Oral Tolerance$425,055
R01 · FY2015 · AI · contact PI
Gut Microbiota in Patients with Multiple Sclerosis$388,099
R01 · FY2015 · NS · contact PI
Circulating MicroRNAs as Disease Biomarkers in Multiple Sclerosis$321,545
UH3 · FY2015 · TR · contact PI
Molecular Analysis of Effector and Regulatory T cell Responses in MS$252,094
P01 · FY2015 · NS · contact PI
Role of LAP positive immune cells in glioblastoma pathogenesis$221,823
R21 · FY2015 · NS · contact PI
Administrative Core$81,470
P01 · FY2015 · NS · contact PI
Role and Therapeutic Value of AHR in Inflammatory Macrophages during GBM$1
R21 · FY2015 · NS
Role of the Innate Immune System in Aging and Development of Alzheimer's Disease$1,666,556
R01 · FY2014 · AG · contact PI
Transcriptional Control of Autoimmunity in the Central Nervous System$1,100,625
P01 · FY2014 · NS · contact PI
Mechanisms of the Induction of Oral Tolerance$423,878
R01 · FY2014 · AI · contact PI
Gut Microbiota in Patients with Multiple Sclerosis$387,096
R01 · FY2014 · NS · contact PI
Role of LAP positive immune cells in glioblastoma pathogenesis$265,438
R21 · FY2014 · NS · contact PI
Role and Therapeutic Value of AHR in Inflammatory Macrophages during GBM$258,926
R21 · FY2014 · NS
Circulating MicroRNAs as Disease Biomarkers in Multiple Sclerosis$249,315
UH2 · FY2014 · TR · contact PI
Molecular Analysis of Effector and Regulatory T cell Responses in MS$226,557
P01 · FY2014 · NS · contact PI
Circulating MicroRNAs as Disease Biomarkers in Multiple Sclerosis$88,458
UH2 · FY2014 · TR · contact PI
Administrative Core$72,994
P01 · FY2014 · NS · contact PI
Role of the Innate Immune System in Aging and Development of Alzheimer's Disease$1,604,691
R01 · FY2013 · AG · contact PI
Transcriptional Control of Autoimmunity in the Central Nervous System$1,128,637
P01 · FY2013 · NS · contact PI
Mechanisms of the Induction of Oral Tolerance$398,445
R01 · FY2013 · AI · contact PI
Molecular Analysis of Effector and Regulatory T cell Responses in MS$326,856
P01 · FY2013 · NS · contact PI
Role of Brain-Specific microRNAs in Suppression of Autoimmune Neuroinflammation$305,058
R01 · FY2013 · NS · contact PI
Circulating MicroRNAs as Disease Biomarkers in Multiple Sclerosis$248,610
UH2 · FY2013 · TR · contact PI
Administrative Core$26,413
P01 · FY2013 · NS · contact PI
Role of the Innate Immune System in Aging and Development of Alzheimer's Disease$1,663,170
R01 · FY2012 · AG · contact PI
Mechanisms of the Induction of Oral Tolerance$423,878
R01 · FY2012 · AI · contact PI
Role of Brain-Specific microRNAs in Suppression of Autoimmune Neuroinflammation$316,122
R01 · FY2012 · NS · contact PI
Gut micro biota in patients with multiple sclerosis$267,750
R21 · FY2012 · NS · contact PI
Mechanisms of the Induction of Oral Tolerance$423,324
R01 · FY2011 · AI · contact PI
Gut micro biota in patients with multiple sclerosis$223,021
R21 · FY2011 · NS · contact PI
Antigen Specific Therapy in CNS Autoimmune Diseases$1,367,567
P01 · FY2010 · NS · contact PI
Role of T-bet, TIM Molecules, and Mucosal Adjuvants in the Induction of Oral Tole$311,574
P01 · FY2010 · NS · contact PI
Mucosal Immunotherapy in a mouse model of Alzheimer's Disease$308,091
R01 · FY2010 · AG · contact PI
Antigen Specific Therapy in CNS Autoimmune Diseases$1,381,465
P01 · FY2009 · NS · contact PI
Mechanisms of the induction of oral tolerance$378,809
R01 · FY2009 · AI · contact PI
Role of T-bet, TIM Molecules, and Mucosal Adjuvants in the Induction of Oral Tole$319,987
P01 · FY2009 · NS · contact PI
Mucosal Immunotherapy in a mouse model of Alzheimer's Disease$311,203
R01 · FY2009 · AG · contact PI
The Effects of Aging in Oral Tolerance$24,020
R03 · FY2009 · TW · contact PI
Antigen Specific Therapy in CNS Autoimmune Diseases$1,361,839
P01 · FY2008 · NS · contact PI
Mechanisms of the induction of oral tolerance$378,809
R01 · FY2008 · AI · contact PI
Role of T-bet, TIM Molecules, and Mucosal Adjuvants in the Induction of Oral Tole$314,697
P01 · FY2008 · NS · contact PI
Mucosal Immunotherapy in a mouse model of Alzheimer's Disease$311,203
R01 · FY2008 · AG · contact PI
The Effects of Aging in Oral Tolerance$47,520
R03 · FY2008 · TW · contact PI
Antigen Specific Therapy in CNS Autoimmune Diseases$1,392,420
P01 · FY2007 · NS · contact PI
Mechanisms of the induction of oral tolerance$386,146
R01 · FY2007 · AI · contact PI
Role of T-bet, TIM Molecules, and Mucosal Adjuvants in the Induction of Oral Tole$369,793
P01 · FY2007 · NS · contact PI
Mucosal Immunotherapy in a mouse model of Alzheimer's Disease$317,554
R01 · FY2007 · AG · contact PI
The Effects of Aging in Oral Tolerance$24,020
R03 · FY2007 · TW · contact PI
Antigen Specific Therapy in CNS Autoimmune Diseases$1,418,846
P01 · FY2006 · NS · contact PI
Mechanisms of the induction of oral tolerance$397,679
R01 · FY2006 · AI · contact PI
Role of T-bet, TIM Molecules, and Mucosal Adjuvants in the Induction of Oral Tole$364,439
P01 · FY2006 · NS · contact PI
Mucosal Immunotherapy in a mouse model of Alzheimer's Disease$327,038
R01 · FY2006 · AG · contact PI
Administrative Core$30,189
P01 · FY2006 · NS · contact PI
Mechanisms of the induction of oral tolerance$407,250
R01 · FY2005 · AI
Immunoregulatory T cells in multiple sclerosis$369,788
R01 · FY2005 · NS
ANTIGEN SPECIFIC THERAPY IN CNS AUTOIMMUNE DISEASES$1,205,782
P01 · FY2004 · NS
Immunoregulatory T cells in multiple sclerosis$369,788
R01 · FY2004 · NS
ANTIGEN SPECIFIC THERAPY IN CNS AUTOIMMUNE DISEASES$1,189,682
P01 · FY2003 · NS
Immunoregulatory T cells in multiple sclerosis$369,788
R01 · FY2003 · NS
ANTIGEN SPECIFIC THERAPY IN CNS AUTOIMMUNE DISEASES$1,174,045
P01 · FY2002 · NS
Immunoregulatory T cells in multiple sclerosis$369,253
R01 · FY2002 · NS
MECHANISMS OF THE INDUCTION OF ORAL TOLERANCE$322,746
R01 · FY2002 · AI
CYTOKINES AND ANTIGEN BINDING AFFINITY ON ORAL TOLERANCE$295,872
P01 · FY2002 · NS
CEREBROSPINAL STUDIES IN MULTIPLE SCLEROSIS$0
M01 · FY2002 · RR
Anti CD40L in treatment of multiple sclerosis$0
U19 · FY2002 · AI
PULSE CYCLOPHOSPHAMIDE FOLLOWED BY TREATMENT W/ITH AVONEX$0
M01 · FY2002 · RR
ANTIGEN SPECIFIC THERAPY IN CNS AUTOIMMUNE DISEASES$1,158,119
P01 · FY2001 · NS
MECHANISMS OF THE INDUCTION OF ORAL TOLERANCE$314,925
R01 · FY2001 · AI
CYTOKINES AND ANTIGEN BINDING AFFINITY ON ORAL TOLERANCE$295,872
P01 · FY2001 · NS
CEREBROSPINAL STUDIES IN MULTIPLE SCLEROSIS$0
M01 · FY2001 · RR
Anti CD40L in treatment of multiple sclerosis$0
U19 · FY2001 · AI
PULSE CYCLOPHOSPHAMIDE FOLLOWED BY TREATMENT W/ITH AVONEX$0
M01 · FY2001 · RR
ANTIGEN SPECIFIC THERAPY IN CNS AUTOIMMUNE DISEASES$1,183,489
P01 · FY2000 · NS
CLIN TRIALS &CLIN MARKERS FOR IMMUNOLOGIC DISEASES$646,654
N01 · FY2000 · AI
IMMUNOREGULATORY T CELLS IN MULTIPLE SCLEROSIS$318,701
R01 · FY2000 · NS
MECHANISMS OF THE INDUCTION OF ORAL TOLERANCE$305,754
R01 · FY2000 · AI
CYTOKINES AND ANTIGEN BINDING AFFINITY ON ORAL TOLERANCE$295,872
P01 · FY2000 · NS
Anti CD40L in treatment of multiple sclerosis$229,321
U19 · FY2000 · AI
CEREBROSPINAL STUDIES IN MULTIPLE SCLEROSIS$0
M01 · FY2000 · RR
PULSE CYCLOPHOSPHAMIDE FOLLOWED BY TREATMENT W/ITH AVONEX$0
M01 · FY2000 · RR